|
|
||||||||
1 Department of Environmental Health Sciences, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205; and 2 Biodynamics Institute, Louisiana State University, Baton Rouge, Louisiana 70803-1800
| |
ABSTRACT |
|---|
|
|
|---|
We examined the effects of ozone
(O3) and endogenous antioxidant
transport on canine peripheral airway function, central airway function, epithelial integrity, and inflammation. Dogs were either untreated or pretreated with probenecid (an anion-transport inhibitor) and exposed for 6 h to 0.2 parts/million
O3. Peripheral airway resistance
(Rpa) and reactivity (
Rpa) were monitored in three sublobar locations before and after exposure to either air or O3. Pulmonary resistance and
transepithelial potential difference in trachea and bronchus were also
recorded. Bronchoalveolar lavage fluid (BALF) was collected before,
during, and after exposure. O3
increased Rpa and
Rpa only in probenecid-treated dogs and in a
location-dependent fashion. Pulmonary resistance and potential difference in bronchus increased after
O3 exposure regardless of
treatment. O3 markedly increased
BALF neutrophils only in untreated dogs. With the exception of hexanal,
O3 did not alter any BALF constituent examined. Probenecid reduced BALF ascorbate, BALF protein,
and plasma urate. We conclude that
1) a 6-h exposure to 0.2 parts/million O3 represents a
subthreshold stimulus in relation to its effects on peripheral airway
function in dogs, 2) antioxidant
transport contributes to the maintenance of normal airway tone and
reactivity under conditions of oxidant stress, 3)
O3-induced changes in Rpa and
Rpa are dependent on location, and
4) peripheral airway hyperreactivity
and inflammation reflect independent responses to
O3 exposure. Finally, although
anion transport mitigates the effect of
O3 on peripheral airway function, it contributes to the development of airway inflammation and may represent a possible target for anti-inflammatory prevention or therapy.
airway hyperreactivity; anion transport; bronchoalveolar lavage; dog; lung; neutrophils; transepithelial potential difference; urate; vitamin C
| |
INTRODUCTION |
|---|
|
|
|---|
EXPOSURE TO RELATIVELY LOW concentrations of ozone
(O3) impairs pulmonary function
and enhances nonspecific airway reactivity in animals (1, 33) and in
normal (21) and asthmatic human subjects (27, 30).
O3 exposure also causes airway
mucosal damage throughout the tracheobronchial tree (8, 25), airway edema, and inflammation (8, 31, 52), and these
O3-induced effects may contribute
to the development of airway hyperreactivity. Potentially
counterbalancing these destructive processes is the airway surface
fluid, which is composed of plasma ultrafiltrate and locally secreted
substances including
-tocopherol, albumin, ascorbate, ceruloplasim,
glutathione, lactoferrin, polyunsaturated fatty acids (PUFA), urate,
and transferrrin (11, 12, 20, 57). All of these substances are capable
to some degree of scavenging oxygen-derived radicals and providing
antioxidant protection to the epithelium (11).
O3-induced changes in small airway
function are difficult to detect by using conventional pulmonary
function tests. Thus most research has focused on
O3-induced damage in the terminal
airways and proximal alveoli (4, 7, 8) and has not addressed the
relationship between peripheral airway injury and changes in peripheral
airway resistance (Rpa) and airway reactivity (
Rpa). O3-induced changes in Rpa and
Rpa have been examined in dogs (19), but those experiments focused
on local responses to high concentrations of
O3 delivered directly into the
peripheral lung via a bronchoscope. Weinman et al. (58, 59) reported
significant O3-induced reductions
in volume-adjusted forced expiratory flow rates measured at
intermediate and low lung volumes (isoV
FEF25-75) in normal human
subjects and interpreted this as impairment of small airway function.
However, despite the development of an inflammatory response, Rpa was
unaffected by O3 exposure (59). It
is important to note that isoV
FEF25-75 and Rpa are unlikely to reflect airway function at the same location. In fact, Rpa is a
measurement believed to be dominated by respiratory bronchioles and
alveolar ducts (39), whereas isoV
FEF25-75 probably reflects
"small" airways of unknown size. This difference may explain why
isoV FEF25-75 and Rpa are not
similarly affected by O3 (58, 59).
However, the relationship between
O3-induced airway inflammation and
impairment of peripheral airway function remains uncertain.
The purpose of this study was to examine the effects of
O3 and endogenous antioxidant
transport on canine Rpa and
Rpa throughout the lung. We first
examined the effect of a 6-h exposure to 0.2 parts/million (ppm)
O3 on Rpa,
Rpa, and several
indexes of inflammation and injury in anesthetized dogs. We monitored
bronchial transepithelial potential difference
(PDbr) and
concentrations of neutrophils, epithelial cells, total protein,
peroxides, and aldehydes in bronchoalveolar lavage fluid (BALF) to
determine whether any of these local markers were associated with
peripheral airway dysfunction. We also documented BALF ascorbate,
trolox equivalent antioxidant capacity (TEAC), and plasma urate to
determine whether these potentially protective peripheral lung
constituents were locally altered after acute O3 exposure. In addition, we
recorded pulmonary resistance
(RL) and tracheal
transepithelial potential difference
(PDtr) to determine whether
changes in these central airway measurements occurred in association
with or as paralleled changes in peripheral airway function.
We then examined the role of antioxidants in modulating oxidant stress
in the lung periphery. Unlike other studies that used exogenous
antioxidant supplementation to protect the lung from oxidant-induced
injury (9, 49, 61), we interfered with endogenous antioxidant activity
and evaluated its effect on
O3-exposed peripheral airways.
Specifically, we used probenecid (an anion-transport inhibitor) to
inhibit antioxidant transport. Probenecid reduces urate levels in human
plasma and nasal lining fluid (47). It also inhibits ascorbate (36, 62)
and glutathione transport (22, 56). Thus, if endogenous antioxidant
activity normally moderates the effect of
O3 on Rpa and
Rpa, then the
inhibition of antioxidant transport with probenecid should amplify
peripheral airway responses to O3.
| |
METHODS |
|---|
|
|
|---|
Experimental Techniques
Animal handling and preparation. Dogs were handled and maintained in accordance with the standards set forth in the Policy and Procedures Manual published by the Johns Hopkins University School of Hygiene and Public Health's Animal Care and Use Committee.Peripheral airway preparation. Male
mongrel dogs were anesthetized with pentobarbital sodium (18 mg/kg iv)
and fentanyl citrate (12 µg/kg iv) and maintained on pentobarbital
sodium (4 mg · kg
1 · h
1
iv). Anesthetic depth was assessed by canthal reflex, heart rate, blood
pressure, and the presence of spontaneous movement or breathing. After
placement of an esophageal balloon, dogs were intubated with a
stainless steel endotracheal tube and ventilated (17 ml/kg) on room air
with a constant-volume ventilator (Harvard Apparatus, Holliston, MA).
End-expiratory CO2 was monitored
with a CO2 analyzer (LB-2,
Beckman, Anaheim, CA) and maintained around 4.5% by adjusting ventilator frequency. Heart rate and blood pressure were monitored noninvasively throughout all experiments (Datascope Accutorr 1A; Datascope, Paramus, NJ). Rectal temperature was monitored with a
telethermometer (Yellow Springs Instrument, Yellow Spring, OH) and
maintained with a warming pad.
Measurement of RL.
Measurements of RL were obtained
by using a forced-oscillation method similar to that previously
described (17). Briefly, with the ventilator momentarily stopped,
airflow (
) was recorded with a
pneumotachograph attached to the tracheal tube and was oscillated
sinusoidally at 4 Hz for 2 s by a loudspeaker while we simultaneously
measured transpulmonary pressure (Ptp). Ptp was measured by using a
differential transducer connecting the esophageal balloon to a catheter
positioned 2 cm past the distal end of the endotracheal tube.
RL was calculated by relating
the real portion (Re) of the pressure differences along the airways to
at the trachea, i.e.,
RL = Re(Ptp)/
.
Measurement of Rpa.
A bronchoscope (Olympus BF Type P10, OD = 5.5 mm, Olympus Corp. of
America, New Hyde Park, NY) was visually guided into a sublobar segment
until the tip occluded the bronchus. A map of the airway branching
pattern was made and used at various times throughout the study to
relocate the sublobar location. A polyethylene catheter (PE 190: 1.2 mm
ID, 1.7 mm OD) attached to a pressure transducer was threaded through
the port of the bronchoscope and was used to record pressure
(Pb) at the tip of the scope.
The wedged segment was ventilated with 200 ml/min of 5%
CO2 in air delivered around the
catheter and through the bronchoscope. Rpa was measured by stopping the
ventilator at functional residual capacity. Under these conditions,
Pb decays to a plateau pressure greater than the surrounding alveolar pressure (atmospheric). Thus Rpa
(cmH2O · ml
1 · s
1) = Pb/[(200 ml/min)(1 min/60
s)].
Measurement of
Rpa.
Airway reactivity (
Rpa = Rpamax
Rpa) was
assessed 30 s after challenge
(Rpamax) with a single dose of
nebulized histamine (50 mg/ml for 30 s).
Acute whole lung exposure to O3. Room air was pumped by a ventilator through a valve that directed air into a stainless steel flow-through chamber containing a low-pressure Hg lamp (the O3 generator) and then into a 4-liter glass mixing chamber. The valve allowed the bulk of the ventilator output to bypass the O3 generator, which was then mixed with the O3 in the glass chamber before entering the lungs via a Teflon tube. The inhaled O3 concentration was sampled every 30 s at the level of the stainless steel endotracheal tube with an O3 monitor (model 1003-AH, Dasibi Environmental, Glendale, CA) and fed back to a computer that adjusted airflow through the valve leading to the O3 generator. Temperature and relative humidity were maintained at 21-23°C and ~55%, respectively.
Measurement of PDtr and PDbr. PDtr was measured via two 3 M KCl/3.5% agar-filled polyethylene-tube bridges (PE 190: 1.2 mm ID, 1.7 mm OD) connected to a pair of calomel half cells and a high-input impedance voltmeter. The recording bridge rested on the inner surface of the midtrachea, and the reference bridge was inserted in the subcutaneous tissue of the neck via a needle. In a similar fashion, two agar-filled bridges were used to monitor PDbr in a small airway located in the lower lobe.
Analysis of BALF. TOTAL AND DIFFERENTIAL CELL COUNTS. Bronchoalveolar lavage (BAL) was done by using three 20-ml aliquots of warm (38°C) isotonic Hanks' balanced salt solution. BALF was delivered via a PE 190 catheter that was threaded through the suction port of the bronchoscope. The 20-ml syringe and PE 190 catheter were used to gently suction the BALF from the wedged sublobar segment. BALF samples were temporarily stored at 4°C and then centrifuged at 4°C for 15 min at 1,350 rpm. The cell pellet from a 5-ml sample was resuspended in 1 ml of supernatant, and a 10-µl sample was placed on a hemocytometer to determine total cell number. Macrophages, lymphocytes, neutrophils, eosinophils, and epithelial cells were counted after being stained with Diff-Quik. Trypan blue exclusion was used to document cell viability.
MEASUREMENT OF ASCORBATE AND TEAC IN BALF. For the ascorbate assay, 10 ml of the BALF were treated at the time of recovery with 3% perchloric acid and stored at
70°C. From
this sample, 0.5 ml of supernatant was mixed with 0.1 ml of
2,4-dinitrophenylhydrazine-thiourea-copper solution and incubated for 3 h at 37°C. The sample was then mixed with 0.75 ml of ice-cold 65%
H2SO4
and allowed to stand at room temperature for an additional 30 min.
Absorbance at 520 nm was then measured (45). Ascorbic acid standards
were measured daily to ensure optimal calibration. The standards were
prepared in 3% perchloric acid to match the samples as closely as
possible. These standards yielded linear calibration curves in the
range of 0.2-2 µg/ml.
A spectrophotometric technique was used to quantify the TEAC of BALF.
This technique measures the relative ability of antioxidants to
scavenge 2,2'-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) radical cation in comparison with the antioxidant efficacy of standard
quantities of a water-soluble vitamin E analog (Trolox). The TEAC of
BALF recovered from air and
O3-exposed lungs was measured at
734 nm in Trolox equivalents (mmol/l) (38).
MEASUREMENT OF PEROXIDES, TOTAL PROTEIN, AND ALDEHYDES IN BALF.
A commercial quantitative peroxide assay (PeroXOquant, Pierce,
Rockford, IL) was used to quantify hydrogen peroxide and organic hydroperoxides in BALF, where the peroxides are expressed as
equivalents of
H2O2
µmol/l. In this assay,
H2O2
reacts with sorbitol to form peroxyl radical, which then oxidizes
ferrous to ferric ion in the presence of xylenol orange to yield a
purple product with a maximum absorbance at 560 nm.
A commercially available Coomassie, dye-binding, colorimetric assay
(Pierce) was used to quantify total BALF protein (µg/ml). Samples
were read spectrophotometrically at 595 nm and evaluated by using a
bovine serum albumin standard curve.
Aldehydes in the BALF supernatant were analyzed as oximes of
pentafluorobenzylhydroxyl-amine by gas chromatography, using electron-capture detection as previously described (13, 14). Briefly, 2 ml of a solution (1-20 µg/l) containing the aldehydes hexanal,
heptanal, or nonanal or 2 ml of BALF were allowed to react
with 0.5 ml of a pentafluorobenzylhydroxyl-amine solution (1.0 mg/ml)
for 2 h. Three drops of 18 N
H2SO4
were then added, and the oximes were extracted with 1 ml of hexane
containing decafluorobiphenyl (50 µg/l) as the internal standard. The
hexane layer was washed with 5 ml of 0.1 N
H2SO4
and dried over anhydrous sodium sulfate. A gas chromatograph (Hewlett
Packard model 5890, series II) with a
63Ni electron-capture detector and
an autosampler (Hewlett Packard 7361A), connected to a cool on-column
injector with electronic pressure control, was used for the analysis.
An HP-5 25 m × 0.2 mm × 0.33-m column with a 5 m × 0.53-mm retention gap was used for the separation. Helium (2.9 ml/min)
was used as a carrier and argon-methane as a makeup gas. The
chromatographic conditions were as follows: detector temperature,
280°C; temperature programming, 50°C for 1 min; temperature
ramp, 5°C/min; final temperature, 220°C. Two microliters of
sample were injected.
Measurement of urate in plasma. Plasma
urate concentrations were assayed by using a uricase reaction, and the
decrease in absorbance of urate was measured spectrophotometrically at
320 nm.
Experimental Protocols
Series 1: Untreated control dogs. RL AND POTENTIAL DIFFERENCE DURING A 6-H EXPOSURE TO 0.2 PPM O3.
Dogs [mean weight = 19.2 ± 1.4 (SE) kg, n = 6] were anesthetized and exposed for 6 h to room-temperature humidified air. The same dogs were exposed 1 wk later for 6 h to 0.2 ppm O3 in humidified room air. RL, PDtr, and PDbr were recorded every 30 min throughout the exposure. Dogs were allowed to recover between the 6- and 24-h measurements. RPA AND
RPA DURING A 6-H EXPOSURE TO 0.2 PPM
O3.
Dogs (mean weight = 20.5 ± 1.5 kg,
n = 6) were anesthetized and exposed
for 6 h to room-temperature humidified air. The same dogs were exposed
1 wk later for 6 h to 0.2 ppm O3
in humidified room air. Rpa and
Rpa were recorded in the right upper
lobe (RUL), left middle lobe (LML), and the right lower lobe (RLL)
before O3 exposure (0 h), after 3 and 6 h of exposure, and at 24 h. We selected 0.2 ppm
O3 for our 6-h exposure protocol
based on estimates made by Morgan et al. (40), who suggested that
breathing at rest 0.2 ppm of O3
through a tracheal tube was roughly equivalent to breathing 0.2 ppm of
O3 through the mouth while
exercising. Thus the anesthetized dogs used in this study were exposed
to O3 concentrations similar to
those used in many human studies.
BALF ANALYSES.
BAL was done in the left upper lobe (LUL) at 0 h, the right middle lobe
(RML) at 3 h, the left lower lobe (LLL) at 6 h, and the cardiac lobe at
24 h, respectively.
Series 2: Probenecid treatment.
RL, POTENTIAL DIFFERENCE, RPA, AND
RPA DURING A 6-H
EXPOSURE TO 0.2 PPM
O3.
1 · day
1)
orally three times a day for 3 days before each exposure. Dogs were
treated with probenecid on the fourth day, which was the first day of
the exposure. Dogs were anesthetized and exposed for 6 h to
room-temperature humidified air. One week later, the same dogs were
pretreated again with probenecid and exposed for 6 h to 0.2 ppm
O3 in humidified room air.
RL,
PDtr, and
PDbr were recorded every 30 min
throughout the experiment. Rpa and
Rpa were recorded in the RUL,
LML, and RLL before O3 exposure (0 h), after 6 h of exposure, and at 18 h postexposure (24 h), respectively.
BALF ANALYSES.
BAL was done in the LUL at 0 h, the RML at 6 h, and the LLL and cardiac
lobe at 24 h, respectively.
Statistical Methods
The Friedman two-way analysis of variance by ranks was used for within-series analyses of RL, PDtr, PDbr, Rpa,
Rpa, and BALF cell/ml data. Nonparametric multiple comparisons were done by using a
Student-Newman-Keuls test for between-treatment comparisons. The
Kruskal-Wallis one-way analysis of variance was used for between-series comparisons of BALF data that were pooled for analysis regardless of
location or time. Either the Student-Newman-Keuls or Dunn's test
applied to ranks was used to compare individual treatment means. All
values are means ± SE. Statistical significance was judged at
P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
RL and Potential Differences During a 6-h Exposure to 0.2 ppm O3
RL recorded before air exposure in untreated dogs was 0.80 ± 0.06 cmH2O · l
1 · s
(n = 6) and was almost identical to the
baseline value (0.83 ± 0.05 cmH2O · l
1 · s) recorded before O3
exposure 1 wk later (Fig 1). After 6 h, a
small but significant difference (P < 0.05) in RL was detected between air (1.01 ± 0.11 cmH2O · l
1 · s)
and O3 exposure (1.33 ± 0.21 cmH2O · l
1 · s).
No significant difference existed between the two treatments by 24 h.
Responses in probenecid-treated dogs were similar.
RL was 0.99 ± 0.04 cmH2O · l
1 · s
(n = 6) before air exposure and was
unchanged (0.99 ± 0.08 cmH2O · l
1 ·s)
1 wk later, before O3 exposure.
O3 increased
(P < 0.05)
RL at 6 h but was not
significantly different from baseline 18 h after the exposure (Fig. 1).
|
Baseline PDtr before air exposure
in control dogs was greater (P < 0.05) than that recorded before O3
exposure (Fig. 2).
PDtr increased during the air
exposure, resulting in values recorded at 6 and 24 h that were similar
to those recorded during O3
exposure, which did not change significantly during the
O3 exposure. Responses in
probenecid-treated dogs were similar.
|
PDbr in untreated dogs decreased (P < 0.05) after 6 h of exposure to either air or O3 when compared with 0-h measurements. However, PDbr was reduced even further 18 h after O3 exposure (P < 0.050), whereas it increased 18 h after air exposure. Similar changes in PDbr occurred in response to O3 in probenecid-treated dogs, whereas no significant changes in PDbr were observed after exposure to air (Fig. 2).
Rpa and
Rpa During a 6-h Exposure to 0.2 ppm
O3
Rpa, to histamine was not affected
(P = 0.197) by
O3.
O3 increased (P < 0.0001) Rpa and
Rpa in probenecid-treated dogs (Fig. 3).
|
Interlobar variation in Rpa and
Rpa was not statistically
significant in untreated control dogs (Fig.
4). In addition, although O3 tended to increase baseline Rpa
(P = 0.053), it did not significantly alter
Rpa (P = 0.562). Significant
interlobar variation was detected in probenecid-treated dogs in
contrast to untreated dogs. Regardless of the type of exposure,
baseline Rpa in the RLL was greater than Rpa in the LML, and Rpa in the
LML was greater than that recorded in the RUL (Fig.
5). O3
increased (P < 0.05) Rpa in the RUL
and LML of probenecid-treated dogs, compared with either baseline (0 h)
or air control. Although the increase in RLL Rpa was not statistically
significant, it was the only location to show an O3-induced increase in airway
reactivity.
Rpa after exposure to
O3 in the RLL was significantly
greater than that recorded in either the LML or the RUL, and this
difference was seen only in probenecid-treated dogs (Fig. 5).
|
|
BALF Analyses
Total and differential cell counts. An average of 40 ± 2 and 40 ± 3 ml (n = 24) of BALF was recovered from sublobar segments in control dogs exposed to air and O3, respectively. Cell viability exceeded 97% in all cases. Except for the 6-h time point where more cells were recovered after O3 exposure than after air exposure (P < 0.05), total number of cells per milliliter of BALF recovered on air and O3 days was not significantly different. Compared with air exposure (2 ± 1%), neutrophils tended to increase after a 6-h exposure to O3 (9 ± 4%) and were significantly (P < 0.05) increased at 24 h (39 ± 11%). No differences were evident between macrophages, lymphocytes, eosinophils, and epithelial cells recovered before, during, or after either exposure (Fig. 6).
|
An average of 44 ± 1.7 and 40 ± 2 ml
(n = 24) of BALF was recovered from
sublobar segments in probenecid-treated dogs exposed to air and
O3, respectively. Cell viability
exceeded 99% in all cases. Total number of cells per milliliter of
BALF recovered on air and O3 days
did not differ significantly. No significant differences were evident
among macrophages, lymphocytes, eosinophils, and epithelial cells
recovered before or after exposure to either air or
O3 (Fig.
7). Although neutrophils in the cardiac
lobe and LLL tended to increase 24 h after each exposure
regimen, a statistically significant change
(P < 0.05) was seen only in the
air-exposed cardiac lobe (6.1 ± 1.6%) when compared with its
baseline value (0 h: 2.2 ± 0.8%,
n = 6).
|
Measurement of ascorbate and TEAC in
BALF. Exposure to
O3 did not significantly alter the
concentration of ascorbic acid or the total antioxidants of BALF
recovered from either control or probenecid-treated dogs at any time
during an experiment (Fig. 8). However, the
concentration of ascorbic acid (0.62 ± 0.04 µg/ml) recovered in
BALF from probenecid-treated dogs pooled regardless of time or location
was significantly reduced when compared with untreated control samples
(1.02 ± 0.06 µg/ml, n = 48, P < 0.0001). Drug treatment did not
affect BALF TEAC (Fig. 8).
|
Measurement of peroxide, total protein, and aldehydes
in BALF. Exposure to
O3 did not significantly alter the
concentrations of peroxide or total protein recovered in BALF from
either control or probenecid-treated dogs at any time during an
experiment (Fig. 9). However, the
concentrations of peroxide (0.67 ± 0.03 µmol/l) and total protein
(247 ± 15.1 µg/ml) recovered in BALF from probenecid-treated dogs
pooled regardless of time or location were significantly reduced when
compared with untreated control samples (1.02 ± 0.06 µg/ml,
n = 48, P < 0.0001; and 203 ± 24.1 µg/ml, n = 48, P < 0.0001, respectively). Finally,
although O3 did not significantly
alter the concentrations of hexanal
(P > 0.107), heptanal
(P > 0.457), or nonanal
(P > 0.572) in a time-specific
fashion, significantly more (P < 0.05) hexanal was recovered from untreated dogs when pooled
samples from the O3 and air
experiments were compared (Fig. 10).
Treatment with probenecid significantly reduced heptanal recovery in
air-exposed bronchi when compared with its untreated counterpart (Fig.
10). No other significant effects were seen after treatment with
probenecid.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study shows that O3 increased peripheral airway resistance and reactivity only in dogs treated with the antioxidant transport inhibitor probenecid, and these effects were heterogeneously distributed throughout the canine lung (Figs. 3 and 5). These observations support the hypothesis that endogenous antioxidant activity moderates the effect of O3 on airway function in the lung periphery.
Although O3 transiently decreased central airway function (Fig. 1), this decrement was not accompanied by any detectable change in PDtr. This suggests that O3 exposure did not grossly injure the tracheal mucosa. However, transepithelial potential difference tended to improve with time in the air-exposed group. Although this may reflect poor initial contact between the recording bridge and the mucosal surface, it is unclear why this would occur only during exposure to air. If this were the case, then we might be missing an O3-induced effect on PDtr. However, we also would be underestimating the significant decrease in PDbr seen in Fig. 2. This decrease in potential difference is believed to reflect O3-induced disruption of the mucosal barrier and is consistent with the enhanced mucosal permeability previously reported in O3-exposed rats and humans (4, 28). Treatment with probenecid did not affect any O3-induced changes in potential difference, although it markedly reduced its variance. This may result from the inhibition of intrapulmonary transport of lipid mediators (5, 6, 60), many of which can modulate ion channel function in airway epithelial cells (2, 34, 55), or a direct effect of probenecid on chloride channels (10).
The marked neutrophilic inflammation observed in untreated control airways (Fig. 6) indicates that O3 penetrates deep into the lung periphery; apparently, at concentrations that are too low to significantly affect normal peripheral airway function (Figs. 3 and 5). The fact that treatment with probenecid inhibits O3-induced inflammation (Fig. 7) while enhancing the effects of O3 on peripheral airway function raises questions concerning the relationship between airway inflammation and airway reactivity. Some studies report good correlations between airway inflammation and airway hyperresponsiveness in dogs (16, 24). However, other studies in rats (15), guinea pigs (41), dogs (35), and humans (51) suggest that neutrophil infiltration does not contribute to the development of airway hyperreactivity caused by acute exposure to high concentrations of O3. Our data (Figs. 3, 4, and 6) are consistent with those obtained from normal human (59) and asthmatic (3) subjects that reveal a dissociation between inflammation and airway function and suggest that a low-dose O3-induced inflammatory response is itself insufficient to significantly alter airway reactivity.
Our data suggest that O3-induced
airway hyperreactivity and inflammation are independent phenomena and
that O3-induced inflammatory cell
influx is dependent on a probenecid-sensitive transport process. Inhibition of leukotrienes in general (53), and leukotriene B4 in particular (54), reduces
O3-induced neutrophil infiltration in dogs. Whether probenecid inhibits leukotriene
B4 transport is unknown, but our
data are consistent with this effect. Other mediators, such as
interleukin-1 (IL-1) (42) and IL-8 (26), also modulate neutrophil
recruitment into the lung, and IL-8 and growth-related oncogene-
have been implicated in the development of
O3-induced inflammation in human
peripheral airways (31). Although the effect of probenecid on cytokine
transport has not been investigated, tenidap (another potent
anion-transport inhibitor) (37) does interfere with the
posttranslational release and maturation of IL-1 (32). Thus it is
possible that the anti-inflammatory activity of probenecid results from
either a direct or indirect effect on either leukotriene or cytokine transport.
Probenecid also interferes with membrane transport of ascorbate (36,
62), glutathione (22, 56), and urate (47), thus altering antioxidant
levels in the lung. We documented a 50-60% decrease in plasma
urate in probenecid-treated dogs, and this may reflect reduced local
concentrations of uric acid in the peripheral lung. Although the
concentration of ascorbic acid and the TEAC of BALF suggest that
O3 had little effect on airway antioxidant levels, probenecid reduced ascorbate levels in BALF (Fig.
8). Although O3 exposure did not
result in significant changes in BALF protein, which can also function
as an antioxidant (23, 46), protein concentrations were reduced by
probenecid (Fig. 9). Theoretically, reductions in ascorbate, urate, and
total protein could account for the increased airway obstruction and
peripheral airway reactivity seen in probenecid-treated animals (Figs.
3 and 5). Probenecid can also inhibit the transport of prostaglandins (5), leukotrienes (43, 60), and cAMP and cGMP (18). However, cyclooxygenase-derived metabolites contribute to
O3-induced changes in baseline
airway function and airway reactivity in dogs (29, 44) and normal
humans (50, 52). Thus the inhibition of membrane transport of
prostaglandins by probenecid would be expected to decrease, not
increase, peripheral airway reactivity (Figs. 3 and 5).
Lipoxygenase-derived metabolites also contribute to
O3-induced airway
hyperresponsiveness in dogs (54); thus interference with leukotriene
membrane transport should also inhibit
O3-induced peripheral airway
hyperreactivity. Finally, the inhibition of either cAMP or cGMP
transport could theoretically increase peripheral airway reactivity.
However, the average histamine-induced
Rpa in air-exposed untreated
dogs (Fig. 3:
Rpa = 0.57 ± 0.06 cmH2O · ml
1 · s
1,
n = 53) was not significantly
different from that seen in dogs treated with probenecid (Fig. 3:
Rpa = 0.61 ± 0.07 cmH2O · ml
1 · s
1,
n = 54, Mann-Whitney
U-test:
P = 0.891). This suggests that inhibition of cyclic nucleotide transport did not affect peripheral airway reactivity in this study. Thus it appears that the enhanced peripheral airway reactivity seen in probenecid-treated dogs probably results from interference with antioxidant transport.
We measured concentrations of the three aldehydes that are produced by ozonation of the most prevalent unsaturated fatty acids (UFA) in lung lipids. It is important to note that UFA undergo ozonation, but only (n-6) PUFA can undergo autoxidation. Thus all three aldehydes reflect the amount of direct ozonation that has occurred. Heptanal is produced from ozonation of palmitolenic acid, an n-7 UFA that is present in the lung, and nonanal from oleic acid, an n-9 UFA that is very prevalent. However, hexanal can be produced either by the ozonation of any n-6 UFA or by the O3-initiated autoxidation of any n-6 PUFA in the lung (13, 14, 48) and is formed in greater amounts than are the other two aldehydes.
The fact that the overall concentration of hexanal was significantly increased in O3-exposed airways (Fig. 10) suggests that the exposure regimen used in this study increased oxidative stress in the lung periphery (13, 48). O3 did not increase either heptanal or nonanal above background levels. Increased concentrations of all three aldehydes were previously reported for BALF samples recovered from rats exposed to 0.5-10 ppm O3 (13, 48). Thus our inability to detect changes in either heptanal or nonanal may simply reflect the relatively low concentration of O3 used in this study.
In summary, O3 did not alter
peripheral airway function in normal dogs but did increase Rpa and
Rpa in probenecid-treated dogs in a location-dependent fashion.
Bronchial but not tracheal mucosal permeability was increased
immediately after and 18 h after
O3 exposure.
O3 markedly increased BALF
neutrophils, and treatment with probenecid inhibited this
O3-induced inflammation. With the
exception of hexanal, O3 did not
alter any BALF constituent examined. Probenecid significantly reduced
BALF ascorbate, BALF total protein, and plasma urate. On the basis of
these observations, we conclude that
1) a 6-h exposure to 0.2 ppm
O3 represents a subthreshold
stimulus in relation to its effects on peripheral airway resistance and
reactivity in normal dogs; 2)
impairment of antioxidant transport contributes to the development of
O3-induced peripheral airway
hyperreactivity in probenecid-treated dogs; 3) peripheral airway hyperreactivity
and inflammation reflect independent responses to
O3 exposure; and
4)
O3-induced inflammation is
dependent on probenecid-sensitive organic anion transporters, which may
represent novel targets for anti-inflammatory drugs.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Drs. Walter Ehrlich and Robert Frank for their critical reviews of an early draft of this manuscript and Sharron McCulloch, Teresa Myers, and Sheng Wang for their superb technical assistance.
| |
FOOTNOTES |
|---|
This work was supported in part by the National Institute of Environmental Health Sciences (NIEHS) Grant ES-O3819 and National Heart, Lung, and Blood Institute Grant R01 HL-50579 (to A. N. Freed); and by the NIEHS Grant ES-08663 (to W. A. Pryor).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: A. N. Freed, Dept. of Environmental Health Sciences, The Johns Hopkins School of Public Health, 615 North Wolfe St., Baltimore, MD 21205 (E-mail: afreed{at}jhsph.edu).
Received 14 September 1998; accepted in final form 28 June 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abraham, W. M.,
A. J. Januszkiewicz,
M. Mingle,
M. Welker,
A. Wanner,
and
M. A. Sackner.
Sensitivity of bronchoprovocation and tracheal mucous velocity in detecting airway responses to O3.
J. Appl. Physiol.
48:
789-793,
1980
2.
Al-Bazzaz, F.,
V. P. Yadava,
and
C. Westenfelder.
Modification of Na and Cl transport in canine tracheal mucosa by prostaglandins.
Am. J. Physiol.
240 (Renal Fluid Electrolyte Physiol. 9):
F101-F105,
1981
3.
Basha, M. A.,
K. B. Gross,
C. J. Gwizdala,
A. H. Haidar,
and
J. Popovich, Jr.
Bronchoalveolar lavage neutrophilia in asthmatic and healthy volunteers after controlled exposure to ozone and filtered purified air.
Chest
106:
1757-1765,
1994
4.
Bhalla, D. K.,
T. T. Crocker,
R. C. Mannix,
and
M. T. Kleinmann.
Relative permeability of nasal, tracheal, and bronchoalveolar mucosa to macromolecules in rats exposed to ozone.
J. Toxicol. Environ. Health
17:
269-283,
1986[Medline].
5.
Bito, L. Z.,
and
R. A. Baroody.
Inhibition of pulmonary prostaglandin metabolism by inhibitors of prostaglandin biotransport (probenecid and bromcresol green).
Prostaglandins
10:
633-639,
1975[Medline].
6.
Bito, L. Z.,
R. A. Baroody,
and
M. E. Reitz.
Dependence of pulmonary prostaglandin metabolism on carrier-mediated transport processes.
Am. J. Physiol.
232 (Endocrinol. Metab. Gastrointest. Physiol. 1):
E383-E387,
1977.
7.
Boatman, E. S.,
S. Sato,
and
R. Frank.
Acute effects of ozone on cat lungs.
Am. Rev. Respir. Dis.
110:
157-169,
1974[Medline].
8.
Castleman, W. L.,
D. L. Dungworth,
L. W. Schwartz,
and
W. S. Tyler.
Acute respiratory bronchiolitis. An ultrastructural and autoradiographic study of epithelial cell injury and renewal in rhesus monkeys exposed to ozone.
Am. J. Pathol.
98:
811-840,
1980[Abstract].
9.
Chatham, M. D.,
H. J. Eppler, Jr.,
L. R. Sauder,
D. Green,
and
T. J. Kulle.
Evaluation of the effects of vitamin C on ozone-induced bronchoconstriction in normal subjects.
Ann. NY Acad. Sci.
498:
269-279,
1987[Medline].
10.
Cloutier, M. M.
Probenecid affects chloride secretion in canine tracheal epithelium.
Am. Rev. Respir. Dis.
135:
1329-1333,
1987[Medline].
11.
Cross, C. E.,
B. Halliwell,
and
A. Allen.
Antioxidant protection: a function of tracheobronchial and gastrointestinal mucus.
Lancet
16:
1328-1329,
1984.
12.
Cross, C. E.,
P. A. Motchnik,
B. A. Bruener,
D. A. Jones,
H. Kaur,
B. N. Ames,
and
B. Halliwell.
Oxidative damage to plasma constituents by ozone.
FEBS Lett.
298:
269-272,
1992[Medline].
13.
Cueto, R.,
G. L. Squadrito,
E. Bermúdez,
and
W. A. Pryor.
Identification of heptanal and nonanal in bronchoalveolar lavage from rats exposed to low levels of ozone.
Biochem. Biophys. Res. Commun.
188:
129-134,
1992[Medline].
14.
Cueto, R.,
G. L. Squadrito,
and
W. A. Pryor.
Quantifying aldehydes and distinguishing aldehydic product profiles from autooxidation and ozonation of unsaturated fatty acids.
Methods Enzymol.
233:
174-182,
1994[Medline].
15.
Evans, T. W.,
J. J. Brokaw,
K. F. Chung,
J. A. Nadel,
and
D. M. McDonald.
Ozone-induced bronchial hyperresponsiveness in the rat is not accompanied by neutrophil influx or increased vascular permeability in the trachea.
Am. Rev. Respir. Dis.
138:
140-144,
1988[Medline].
16.
Fabbri, M. L.,
H. Aizawa,
S. E. Alpert,
E. H. Walters,
P. M. O'Byrne,
B. D. Gold,
J. A. Nadel,
and
M. J. Holtzman.
Airway hyperresponsiveness and changes in cell counts in bronchoalveolar lavage after ozone exposure in dogs.
Am. Rev. Respir. Dis.
129:
288-291,
1984[Medline].
17.
Fuller, S. D.,
and
A. N. Freed.
Partitioning of pulmonary function in rabbits during cholinergic stimulation.
J. Appl. Physiol.
78:
1242-1249,
1995
18.
Geary, C. A.,
M. F. Goy,
and
R. C. Boucher.
Synthesis and vectorial export of cGMP in airway epithelium: expression of soluble and CNP-specific guanylate cyclases.
Am. J. Physiol.
265 (Lung Cell. Mol. Physiol. 9):
L598-L605,
1993
19.
Gertner, A.,
B. Bromberger-Barnea,
R. Traystman,
and
H. Menkes.
Effects of ozone on peripheral lung reactivity.
J. Appl. Physiol.
55:
777-784,
1983
20.
Giamalva, D.,
D. F. Church,
and
W. A. Pryor.
A comparison of the rates of ozonation of biological antioxidants and oleate and linoleate esters.
Biochem. Biophys. Res. Commun.
133:
773-779,
1985[Medline].
21.
Golden, J. A.,
J. A. Nadel,
and
H. A. Boushey.
Bronchial hyperirritabilty in healthy subjects after exposure to ozone.
Am. Rev. Respir. Dis.
118:
287-294,
1978[Medline].
22.
Hagen, T. M.,
L. A. Brown,
and
D. P. Jones.
Protection against paraquat-induced injury by exogenous GSH in pulmonary alveolar type II cells.
Biochem. Pharmacol.
35:
4537-4542,
1986[Medline].
23.
Halliwell, B.
Commentary: Albumin
an important extracellular antioxidant?
Biochem. Pharmacol.
37:
569-571,
1988[Medline].
24.
Holtzman, M. J.,
L. M. Fabbri,
P. M. O'Byrne,
B. D. Gold,
H. Aizawa,
E. H. Walters,
S. E. Alpert,
and
J. A. Nadel.
Importance of airway inflammation for hyperresponsiveness induced by ozone.
Am. Rev. Respir. Dis.
127:
686-690,
1983[Medline].
25.
Hyde, D. M.,
W. C. Hubbard,
V. Wong,
R. Wu,
K. Pinkerton,
and
C. G. Plopper.
Ozone-induced acute tracheobronchial epithelial injury: relationship to granulocyte emigration in the lung.
Am. J. Respir. Cell Mol. Biol.
6:
481-497,
1992.
26.
Inoue, H.,
P. P. Massion,
I. F. Ueki,
K. M. Grattan,
M. Hara,
A. F. Dohrman,
B. Chan,
J. A. Lausier,
J. A. Golden,
and
J. A. Nadel.
Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils.
Am. J. Respir. Cell Mol. Biol.
11:
651-663,
1994[Abstract].
27.
Jorres, R.,
D. Nowak,
H. Magnussen,
P. Speckin,
and
S. Koschyk.
The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis.
Am. J. Respir. Crit. Care Med.
153:
56-64,
1996[Abstract].
28.
Kehrl, H. R.,
L. M. Vincent,
R. J. Kowalsky,
D. H. Horstman,
J. J. O'Neil,
W. H. McCartney,
and
P. A. Bromberg.
Ozone exposure increases respiratory epithelial permeability in humans.
Am. Rev. Respir. Dis.
135:
1124-1128,
1987[Medline].
29.
Kleeberger, S. R.,
J. Kolbe,
N. F. Adkinson,
S. P. Peters,
and
E. W. Spannhake.
The role of mediators in the response of the canine peripheral lung to 1 ppm ozone.
Am. Rev. Respir. Dis.
137:
321-325,
1988[Medline].
30.
Kreit, J. W.,
K. B. Gross,
T. B. Moore,
T. J. Lorenzen,
J. d'Arcy,
and
W. L. Eschenbacher.
Ozone-induced changes in pulmonary function and bronchial responsiveness in asthmatics.
J. Appl. Physiol.
66:
217-222,
1989
31.
Krishna, M. T.,
J. Madden,
L. M. Teran,
G. Biscione,
L. C. K. Lau,
N. J. Withers,
T. Sandström,
I. Mudway,
F. J. Kelly,
A. Walls,
A. J. Frew,
and
S. T. Holgate.
Effects of 0.2 ppm ozone on biomarkers of inflammation in bronchoalveolar lavage fluid and bronchial mucosa of healthy subjects.
Eur. Respir. J.
11:
1294-1300,
1998[Abstract].
32.
Laliberte, R.,
D. Perregaux,
L. Svensson,
C. J. Pazoles,
and
C. A. Gabel.
Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1 beta production from ATP-treated monocytes and macrophages.
J. Immunol.
153:
2168-2179,
1994[Abstract].
33.
Lee, L. Y.,
E. R. Bleecker,
and
J. A. Nadel.
Effect of ozone on bronchomotor responses to inhaled histamine aerosol in dogs.
J. Appl. Physiol.
43:
626-631,
1977
34.
Leikauf, G. D.,
I. F. Ueki,
J. H. Widdicombe,
and
J. A. Nadel.
Alteration of chloride secretion across canine tracheal epithelium by lipoxygenase products of arachidonic acid.
Am. J. Physiol.
250 (Renal Fluid Electrolyte Physiol. 19):
F47-F53,
1986.
35.
Li, Z.,
E. E. Daniel,
C. G. Lane,
M. A. Arnaout,
and
P. M. O'Byrne.
Effect of an anti-Mo1 MAb on ozone-induced airway inflammation and airway hyperresponsiveness in dogs.
Am. J. Physiol.
263 (Lung Cell. Mol. Physiol. 7):
L723-L726,
1992
36.
Martin, M.,
B. Ferrier,
and
F. Roch-Ramel.
Renal excretion of ascorbic acid in the rat: a micropuncture study.
Am. J. Physiol.
244 (Renal Fluid Electrolyte Physiol. 13):
F335-F341,
1983.
37.
McNiff, P.,
L. Svensson,
C. J. Pazoles,
and
C. A. Gabel.
Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance.
J. Immunol.
153:
2180-2193,
1994[Abstract].
38.
Miller, N. J.,
and
C. A. Rice-Evans.
Spectrophotometric determination of antioxidant activity.
Redox Rept.
2:
161-171,
1996.
39.
Mitzner, W.
Collateral ventilation.
In: The Lung: Scientific Foundations, edited by R. G. Crystal,
and J. B. West. Philadelphia, PA: Raven, 1997, p. 1425-1435.
40.
Morgan, M. S.,
P. Meyer,
R. Holub,
and
R. Frank.
Overall and regional lung function in dogs exposed acutely to ozone.
Environ. Res.
41:
546-557,
1986[Medline].
41.
Murlas, C. G.,
and
J. H. Roum.
Sequence of pathologic changes in the airway mucosa of guinea pigs during ozone-induced bronchial hyperreactivity.
Am. Rev. Respir. Dis.
131:
314-320,
1985[Medline].
42.
Narimanbekov, I. O.,
and
H. J. Rozycki.
Effect of IL-1 blockade on inflammatory manifestations of acute ventilator-induced lung injury in a rabbit model.
J. Appl. Physiol.
21:
239-254,
1995.
43.
Nguyen, T.,
and
S. Gupta.
Leukotriene C4 secretion from normal murine mast cells by a probenecid-sensitive and multidrug resistance-associated protein-independent mechanism.
J. Immunol.
158:
4916-4920,
1997[Abstract].
44.
O'Byrne, P. M.,
E. H. Walters,
H. Aizawa,
L. M. Fabbri,
M. J. Holtzman,
and
J. A. Nadel.
Indomethacin inhibits the airway hyperresponsiveness but not the neutrophil influx induced by ozone in dogs.
Am. Rev. Respir. Dis.
130:
220-224,
1984[Medline].
45.
Omaye, S. T.,
J. D. Turnball,
and
H. E. Sauberlich.
Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids.
Methods Enzymol.
62:
3-11,
1979[Medline].
46.
Pacht, E. R.,
and
W. B. Davis.
Role of transferrin and ceruloplasmin in antioxidant activity of lung epithelial lining fluid.
J. Appl. Physiol.
64:
2092-2099,
1988
47.
Peden, D. B.,
M. Swiersz,
K. Ohkubo,
B. Hahn,
B. Emery,
and
M. A. Kaliner.
Nasal secretion of the ozone scavenger uric acid.
Am. Rev. Respir. Dis.
148:
455-461,
1993[Medline].
48.
Pryor, W. A.,
E. Bermudez,
R. Cueto,
and
G. L. Squadrito.
Detection of aldehydes in brochoalveolar lavage of rats exposed to ozone.
Fundam. Appl. Toxicol.
34:
148-156,
1996[Medline].
49.
Romieu, I.,
F. Meneses,
M. Ramirez,
S. Ruiz,
R. P. Padilla,
J. J. Sienra,
M. Gerber,
L. Grievink,
R. Dekker,
I. Walda,
and
B. Brunekreef.
Antioxidant supplementation and respiratory functions among workers exposed to high levels of ozone.
Am. J. Respir. Crit. Care Med.
158:
226-232,
1998
50.
Schelegle, E. S.,
W. C. Adams,
and
A. D. Siefkin.
Indomethacin pretreatment reduces ozone-induced pulmonary function decrements in human subjects.
Am. Rev. Respir. Dis.
136:
1350-1354,
1987[Medline].
51.
Schelegle, E. S.,
A. D. Siefkin,
and
R. J. McDonald.
Time course of ozone-induced neutrophilia in normal humans.
Am. Rev. Respir. Dis.
143:
1353-1358,
1991[Medline].
52.
Seltzer, J.,
B. G. Bigby,
M. Stulbarg,
M. J. Holtzman,
J. A. Nadel,
I. F. Ueki,
G. D. Leikauf,
E. J. Goetzl,
and
H. A. Boushey.
O3-induced change in bronchial reactivity to methacholine and airway inflammation in humans.
J. Appl. Physiol.
60:
1321-1326,
1986
53.
Stevens, W. H. M.,
C. G. Lane,
M. J. Woolley,
R. Ellis,
P. Tagari,
C. Black,
A. Ford-Hutchinson,
and
P. M. O'Byrne.
Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs.
J. Appl. Physiol.
76:
1583-1588,
1994
54.
Stevens, W. H. M.,
C. VanderHeyden,
J. Wattie,
C. G. Lane,
W. Smith,
and
P. M. O'Byrne.
Effect of a leukotriene B4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs.
Am. J. Respir. Crit. Care Med.
152:
1443-1448,
1995[Abstract].
55.
Tamaoki, J.,
T. Kanemura,
N. Sakai,
K. Isono,
A. Chiyotani,
F. Yamauchi,
T. Takizawa,
and
K. Konno.
Prostaglandin D2 increases Cl secretion across canine tracheal epithelium through cyclooxygenase stimulation and cAMP production.
Acta Physiol. Scand.
145:
1-6,
1992[Medline].
56.
Versantvoort, C. H.,
T. Bagrij,
K. A. Wright,
and
P. R. Twentyman.
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP).
Int. J. Cancer
63:
855-862,
1995[Medline].
57.
Wayner, D. D. M.,
G. W. Burton,
K. U. Ingold,
L. R. C. Barclay,
and
S. J. Locke.
The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma.
Biochim. Biophys. Acta
924:
408-419,
1987[Medline].
58.
Weinmann, G. G.,
S. M. Bowes,
M. W. Gerbase,
A. W. Kimball,
and
R. Frank.
Response to acute ozone exposure in healthy men: results of a screening procedure.
Am. J. Respir. Crit. Care Med.
151:
33-40,
1995[Abstract].
59.
Weinmann, G. G.,
M. C. Liu,
D. Proud,
M. Weidenbach-Gerbase,
W. Hubbard,
and
R. Frank.
Ozone exposure in humans: inflammatory, small, and peripheral airway responses.
Am. J. Respir. Crit. Care Med.
152:
1175-1182,
1995[Abstract].
60.
Westcott, J. Y.,
S. Ono,
M. Oka,
K. Jones,
and
N. F. Voelkel.
Inactivation of peptidoleukotrienes in the isolated perfused rat lung.
Arch. Biochem. Biophys.
306:
44-51,
1993[Medline].
61.
Yeadon, M., D. Wilkinson, V. Darley-Usmar, V. J. O'Leary, and A. N. Payne. Mechanisms contributing to
ozone-induced bronchial hyperreactivity in guinea-pigs.
Pulmon. Pharmacol. 39-50, 1992.
62.
Zhou, A.,
J. H. Nielson,
O. Farver,
and
N. A. Thorn.
Transport of ascorbic acid and dehydroascorbic acid by pancreatic islet cells from neonatal rats.
Biochem. J.
274:
739-744,
1991.
This article has been cited by other articles:
![]() |
R. FRANK, M. C. LIU, E. W. SPANNHAKE, S. MLYNAREK, K. MACRI, and G. G. WEINMANN Repetitive Ozone Exposure of Young Adults . Evidence of Persistent Small Airway Dysfunction Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1253 - 1260. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||